Australia markets closed

Ono Pharmaceutical Co., Ltd. (4528.T)

Tokyo - Tokyo Delayed price. Currency in JPY
Add to watchlist
2,219.50+1.50 (+0.07%)
At close: 03:15PM JST
Currency in JPY

Valuation measures4

Market cap (intra-day) 1.04T
Enterprise value 845.95B
Trailing P/E 8.32
Forward P/E 13.95
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.12
Price/book (mrq)1.31
Enterprise value/revenue 1.68
Enterprise value/EBITDA 4.65

Trading information

Stock price history

Beta (5Y monthly) 0.17
52-week change 3-13.16%
S&P500 52-week change 325.51%
52-week high 32,966.50
52-week low 32,097.50
50-day moving average 32,238.68
200-day moving average 32,499.06

Share statistics

Avg vol (3-month) 32.09M
Avg vol (10-day) 31.81M
Shares outstanding 5469.65M
Implied shares outstanding 6474.03M
Float 8383.27M
% held by insiders 115.55%
% held by institutions 147.30%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 480
Forward annual dividend yield 43.61%
Trailing annual dividend rate 380.00
Trailing annual dividend yield 33.61%
5-year average dividend yield 42.08
Payout ratio 430.01%
Dividend date 3N/A
Ex-dividend date 427 Sept 2024
Last split factor 25:1
Last split date 329 Mar 2016

Financial highlights

Fiscal year

Fiscal year ends 31 Mar 2024
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 25.46%
Operating margin (ttm)13.90%

Management effectiveness

Return on assets (ttm)11.16%
Return on equity (ttm)16.56%

Income statement

Revenue (ttm)502.67B
Revenue per share (ttm)1,047.21
Quarterly revenue growth (yoy)4.30%
Gross profit (ttm)N/A
EBITDA 178.43B
Net income avi to common (ttm)127.98B
Diluted EPS (ttm)266.60
Quarterly earnings growth (yoy)2.10%

Balance sheet

Total cash (mrq)204.6B
Total cash per share (mrq)435.64
Total debt (mrq)8.86B
Total debt/equity (mrq)1.11%
Current ratio (mrq)3.99
Book value per share (mrq)1,688.42

Cash flow statement

Operating cash flow (ttm)110.66B
Levered free cash flow (ttm)50.1B